Spatiotemporally programming cytokine immunotherapies through protein engineering
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Spatiotemporally programming cytokine immunotherapies through protein engineering
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-07-06
DOI
10.1111/imr.13234
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer gene therapy bears fruit
- (2023) Timothy P. Cripe MOLECULAR THERAPY
- IFNγ binding to extracellular matrix prevents fatal systemic toxicity
- (2023) Josephine Kemna et al. NATURE IMMUNOLOGY
- An IL‐12‐Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors
- (2023) Pengwen Chen et al. Advanced Science
- Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas
- (2023) Jordan A. Stinson et al. CLINICAL CANCER RESEARCH
- Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors
- (2023) Aparna Raghavachar Chakravarti et al. Molecular Pharmaceutics
- T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
- (2023) Deborah Meyran et al. Science Translational Medicine
- A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
- (2023) Miro E. Raeber et al. EBioMedicine
- The abscopal effect in patients with cancer receiving immunotherapy
- (2023) Blessie Elizabeth Nelson et al. Med
- An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses
- (2023) Eva Gutierrez et al. Med
- Maximizing response to intratumoral immunotherapy in mice by tuning local retention
- (2022) Noor Momin et al. Nature Communications
- Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
- (2022) Yash Agarwal et al. Nature Biomedical Engineering
- A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
- (2022) Diyuan Xue et al. Science Immunology
- Engineering interferons and interleukins for cancer immunotherapy
- (2022) Patrick G. Holder et al. ADVANCED DRUG DELIVERY REVIEWS
- Intratumorally anchored cytokine therapy
- (2022) K. Dane Wittrup et al. Expert Opinion on Drug Delivery
- Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression
- (2022) Christopher J. Nirschl et al. Cancer Immunology Research
- Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker
- (2022) Aslan Mansurov et al. Nature Biomedical Engineering
- Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
- (2022) Karim Chamie et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
- (2022) Elena Garralda et al. JOURNAL OF CLINICAL ONCOLOGY
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- (2022) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
- (2022) Sarah C. Cowles et al. mAbs
- 749P ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study
- (2022) H. Läubli et al. ANNALS OF ONCOLOGY
- PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
- (2022) Laura Codarri Deak et al. NATURE
- PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
- (2022) Masao Hashimoto et al. NATURE
- A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
- (2022) Alfredo Quijano-Rubio et al. NATURE BIOTECHNOLOGY
- Emerging principles of cytokine pharmacology and therapeutics
- (2022) Robert A. Saxton et al. NATURE REVIEWS DRUG DISCOVERY
- Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
- (2022) Emi A. Lutz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of engineered immune cell therapies
- (2022) Darrell J. Irvine et al. SCIENCE
- IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein
- (2022) Silvia Gaggero et al. Science Immunology
- Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
- (2021) Jennifer A. Foltz et al. CLINICAL CANCER RESEARCH
- A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
- (2021) Eric J. Hsu et al. Nature Communications
- Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
- (2021) Jingya Guo et al. CELL RESEARCH
- GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
- (2021) Premal H. Thaker et al. CLINICAL CANCER RESEARCH
- Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes
- (2021) Jason M. Schenkel et al. IMMUNITY
- Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys
- (2021) Jared E. Lopes et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- An engineered IL-2 partial agonist promotes CD8+ T cell stemness
- (2021) Fei Mo et al. NATURE
- An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
- (2021) Yuanming Xu et al. Cancer Immunology Research
- Switchable immune modulator for tumor-specific activation of anticancer immunity
- (2021) Yu Zhao et al. Science Advances
- A reservoir of stem-like CD8 + T cells in the tumor-draining lymph node preserves the ongoing anti-tumor immune response
- (2021) Kelli A. Connolly et al. Science Immunology
- Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates
- (2021) Philipp Steiner et al. BLOOD
- Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory
- (2021) Jardin A. Leleux et al. PLoS One
- Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
- (2021) Xuezhi Cao et al. Nature Communications
- Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade
- (2021) Chensu Wang et al. Cell Reports
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Engineered immunogen binding to alum adjuvant enhances humoral immunity
- (2020) Tyson J. Moyer et al. NATURE MEDICINE
- A Role for Dogs in Advancing Cancer Immunotherapy Research
- (2020) Steven Dow Frontiers in Immunology
- Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
- (2020) Aslan Mansurov et al. Nature Biomedical Engineering
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Intratumoral Immunotherapy: from Trial Design to Clinical Practice
- (2020) Stephane Champiat et al. CLINICAL CANCER RESEARCH
- Localized Interleukin-12 for Cancer Immunotherapy
- (2020) Khue G. Nguyen et al. Frontiers in Immunology
- Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
- (2020) Futa Mimoto et al. Cell Reports
- Engineering IL-2 to Give New Life to T Cell Immunotherapy
- (2020) Willem W. Overwijk et al. Annual Review of Medicine
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models
- (2019) Adrienne Rothschilds et al. OncoImmunology
- Interferons α and β in cancer: therapeutic opportunities from new insights
- (2019) Ernest C. Borden NATURE REVIEWS DRUG DISCOVERY
- Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
- (2019) Linh T. Nguyen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
- (2019) Mohammed M. Milhem et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted antibody and cytokine cancer immunotherapies through collagen affinity
- (2019) Jun Ishihara et al. Science Translational Medicine
- Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
- (2019) Noor Momin et al. Science Translational Medicine
- Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
- (2019) Xian-Yang Li et al. Cancer Discovery
- Trans-endocytosis of intact IL-15Rα–IL-15 complex from presenting cells into NK cells favors signaling for proliferation
- (2019) Olga M. Anton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Tumor elastography and its association with collagen and the tumor microenvironment.
- (2018) Johannes Riegler et al. CLINICAL CANCER RESEARCH
- Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
- (2018) Benjamin Ribba et al. CLINICAL CANCER RESEARCH
- Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
- (2018) Li Tang et al. NATURE BIOTECHNOLOGY
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
- (2018) Jonathan T. Sockolosky et al. SCIENCE
- Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
- (2018) Chun Gwon Park et al. Science Translational Medicine
- Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation
- (2018) Maxime Danilo et al. Cell Reports
- Prospects of IL-2 in Cancer Immunotherapy
- (2018) Hani Choudhry et al. Biomed Research International
- Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells
- (2018) Keunok Jung et al. OncoImmunology
- Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
- (2018) Cornelia Hutmacher et al. ADVANCED DRUG DELIVERY REVIEWS
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
- (2018) Anandaroop Mukhopadhyay et al. GENE THERAPY
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
- (2017) Megan Lo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins
- (2016) Dario Venetz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The extracellular matrix: Tools and insights for the “omics” era
- (2016) Alexandra Naba et al. MATRIX BIOLOGY
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy
- (2016) Alice Tzeng et al. Cell Reports
- Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines
- (2016) Zulmarie Perez Horta et al. OncoImmunology
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
- (2015) Brian Rogers et al. CURRENT PHARMACEUTICAL DESIGN
- Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
- (2015) Jamie B. Spangler et al. IMMUNITY
- Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
- (2015) Alice Tzeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The immunocytokine NHS-IL12 as a potential cancer therapeutic
- (2015) Jonathan Fallon et al. Oncotarget
- Intratumoral Immunization: A New Paradigm for Cancer Therapy
- (2014) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
- (2014) L. Baudino et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- High efficiency cell-specific targeting of cytokine activity
- (2014) Geneviève Garcin et al. Nature Communications
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
- (2011) Brandon Kwong et al. BIOMATERIALS
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects
- (2011) Lindsey R. Baden et al. JOURNAL OF INFECTIOUS DISEASES
- Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12
- (2010) David A. Zaharoff et al. JOURNAL OF IMMUNOTHERAPY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents
- (2009) Raymond P. Donnelly et al. Annals of the New York Academy of Sciences
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
- (2009) Ahmad A. Tarhini et al. CANCER
- Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12
- (2009) D. A. Zaharoff et al. CANCER RESEARCH
- Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries
- (2009) Jerry M. Thomas et al. PROTEIN SCIENCE
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
- (2009) J. Bostrom et al. SCIENCE
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- Tumour endoproteases: the cutting edge of cancer drug delivery?
- (2008) J M Atkinson et al. BRITISH JOURNAL OF PHARMACOLOGY
- Factors determining antibody distribution in tumors
- (2008) G THURBER et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started